Terms: = Lung cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
3 results:
1. Molecular Characterization and clinical Relevance of Metabolic Expression Subtypes in Human cancers.
Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D; Ge Z; Li J; Thomas GV; Birsoy K; Liu L; Zhang H; Zhao Z; Marchand C; Weinstein JN; ; Bathe OF; Liang H
Cell Rep; 2018 Apr; 23(1):255-269.e4. PubMed ID: 29617665
[TBL] [Abstract] [Full Text] [Related]
2. Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.
Duan L; Hu X; Jin Y; Liu R; You Q
BMC Cancer; 2016 Apr; 16():276. PubMed ID: 27090386
[TBL] [Abstract] [Full Text] [Related]
3. The chimeric transcript runx1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer.
Ishikawa R; Amano Y; Kawakami M; Sunohara M; Watanabe K; Kage H; Ohishi N; Yatomi Y; Nakajima J; Fukayama M; Nagase T; Takai D
Jpn J Clin Oncol; 2016 Feb; 46(2):185-9. PubMed ID: 26685324
[TBL] [Abstract] [Full Text] [Related]
